DOLF Presentations at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (Virtual, November 2021)
Symposium: Clinical development of new treatments to support the global elimination of onchocerciasis. GJ Weil, C Hanson, N Opoku, A Hoerauf, S. Specht, M Sullivan.
Coverage and impact of a single dose of ivermectin, DEC and albendazole for lymphatic filariasis: results from a community study K. Kaliannagounder et al (India).
Moxidectin efficacy in single dose combination therapies with albendazole and diethylcarbamazine for treatment of lymphatic filariasis in Côte d’Ivoire: preliminary results from a randomized controlled trial. BG Koudou et al (Côte d’Ivoire).
Safety of Single Dose Moxidectin Combination Therapy for Bancroftian Filariasis. CM Bjerum, P Budge, BG Koudou, et al (Côte d’Ivoire).
Population Pharmacokinetics of Ivermectin in Lymphatic Filariasis Patients and Healthy Individuals. AM Alshehri, CM Bjerum, CL King, et al.
The impact of mass drug administration with a triple drug regimen (ivermectin, diethylcarbamazine and albendazole) on lymphatic filariasis in Papua New Guinea and implications for post-MDA surveillance. K Bun, M Laman, M Payne, D Tische, G Weil, CL King, et al.
Assessing acceptability of mass drug administration for lymphatic filariasis as part of routine monitoring and evaluation: feasibility and operational implications. C Thisckstun, K Bun, Dilliott D, CL King, et al (East New Britain, Papua New Guinea)
Frontline health worker and community health volunteer experiences with delivery of mass drug administration using triple drug therapy for lymphatic filariasis in Papua New Guinea: a mixed method study. A Krentel, K Bun, D Dilliott, CL King, et al.
Other presentations at the ASTMH Meeting from Washington University helminth parasite researchers (Fischer, Budge, Mitreva, and Weil labs)
A promising new serologic test for evaluating the success of elimination programs for bancroftian filariasis. S.E Greene, GJ Weil, PU Fischer, et al.
Identifying the potential value of short-course doxycycline added to WHO’s hygiene-based Essential Care Package to improve the physical and quality of life measures of ~1800 patients with lymphedema caused by Lymphatic Filariasis or podoconiosis: Individual placebo-controlled clinical trials in six countries. LB Debrah, P Budge, et al.
Morphological and genomic characterization of Paragonimus from Cameroon indicate a distinct clade of lung flukes. L Sanchez-DiMaggio, K Fischer, P Fischer, et al.
Discovery for Loa loa cross-reactive biomarkers responsible for false-positive lymphatic filariasis rapid diagnostic tests. LY Djune, M Hertz, P Budge, et al.